Commodore Capital LP Boosts Stake in PepGen, Inc. $PEPG

Commodore Capital LP increased its stake in PepGen, Inc. (NASDAQ:PEPG) by 31.6% during the first quarter, Holdings Channel.com reports. The firm owned 4,475,000 shares of the company’s stock after purchasing an additional 1,075,000 shares during the quarter. Commodore Capital LP owned 0.06% of PepGen worth $7,921,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of PEPG. China Universal Asset Management Co. Ltd. grew its holdings in PepGen by 94.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock valued at $73,000 after purchasing an additional 5,453 shares during the period. Burkehill Global Management LP bought a new position in shares of PepGen in the third quarter worth about $46,000. Jefferies Financial Group Inc. bought a new position in shares of PepGen in the fourth quarter worth about $89,000. Militia Capital Partners LP purchased a new position in shares of PepGen during the 3rd quarter valued at about $72,000. Finally, ADAR1 Capital Management LLC lifted its position in shares of PepGen by 81.0% during the 3rd quarter. ADAR1 Capital Management LLC now owns 36,842 shares of the company’s stock valued at $170,000 after buying an additional 16,490 shares in the last quarter. 58.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. Wedbush lowered their price target on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Craig Hallum started coverage on shares of PepGen in a research report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 price target for the company. Weiss Ratings cut shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. Finally, HC Wainwright restated a “buy” rating on shares of PepGen in a research report on Thursday, May 21st. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, PepGen presently has an average rating of “Moderate Buy” and an average price target of $11.50.

PepGen Stock Performance

NASDAQ:PEPG opened at $1.93 on Monday. The stock has a 50-day moving average price of $1.76 and a 200 day moving average price of $3.39. The stock has a market capitalization of $133.50 million, a P/E ratio of -1.10 and a beta of 1.88. PepGen, Inc. has a 12-month low of $1.01 and a 12-month high of $7.80.

PepGen (NASDAQ:PEPG) last issued its earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. On average, research analysts predict that PepGen, Inc. will post -1.2 earnings per share for the current fiscal year.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).